Why the study?
Does the ACE insertion/deletion polymorphism predict the therapeutic efficacy of ACE inhibitors and prognosis in patients with progressive IgA nephropathy?
Does the ACE insertion/deletion polymorphism predict the therapeutic efficacy of ACE inhibitors and prognosis in patients with progressive IgA nephropathy?
The ACE I/D polymorphism (DD genotype) may serve as a prognostic marker and predictor of ACE inhibitor efficacy in patients with IgA nephropathy.
Hypothesis-generating for ACE I/D genotyping in IgA nephropathy; prospective validation required before clinical use.
Summary: Clinical studies revealed that angiotensin converting enzyme (ACE) inhibitor reduces proteinuria and attenuates progressive decline in renal function in IgA nephropathy. Recent studies by us and others have demonstrated that the homozygote of the D allele (DD) of the ACE insertion/deletion (I/D) polymorphism is a potential risk factor for poor prognosis in IgA nephropathy, and that this deletion polymorphism predicts the therapeutic efficacy of ACE inhibition on proteinuria and, potentially, on progressive deterioration of renal function in patients with the nephropathy.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: